Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of somatostatin in the incidence of post-ERCP pancreatitis
IRCT20080921001264N11Phase 4Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of somatostatin in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) and pancreatitis, sponsored by Golestan University of Medical Sciences. Started Mar 2018; status: completed.
02
Drugs
somatostatin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)pancreatitis
Beyond the preview
Go deeper on IRCT20080921001264N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20080921001264N11.